Date:11/2/2010

ovisions of the Private Securities Litigation Reform Act of 1995. These include, but are not limited to, statements relating to the anticipated initiation of Anthera's clinical studies, anticipated duration and expected results of these studies, and the progression of Anthera's products through future stages of clinical development. These forward-looking statements are based on Anthera's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially as set forth in the Company's public filings with the Securities and Exchange Commission, including Anthera's Quarterly Report on Form 10-Q for the quarter ended June 30, 2010. Anthera disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.

CONTACT: Bianca Nery of Anthera Pharmaceuticals, Inc., bnery@anthera.com or 510-856-5586.ANTHERA PHARMACEUTICALS, INC.A Development Stage CompanySTATEMENT OF OPERATIONS(unaudited)Three Months Ended September 30,Nine Months Ended September 30,2010200920102009OPERATING EXPENSE:  Research and development

$
,885,125$
2,525,948$
8,565,088$
7,727,129  General and administrative

1,510,021884,9084,244,0002,730,482Total operating expense

8,395,1463,410,85622,809,08810,457,611LOSS FROM OPERATIONS:

(8,395,146)(3,410,856)(22,809,088)(10,457,611)OTHER INCOME (EXPENSE):Interest and other income

61,606-76,56221,559Interest and other expense

-(193,556)(4,641,169)(289,776)Total other income (expense)

61,606(193,556)(4,564,607)(268,217)NET LOSS

$  (8,333,540)$   (3,604,412)$  (27,373,695)$   (10,725,828)Net loss per share--basic and diluted

$
(0.36)$
(2.37)$
(1.40)$
(7.16) Weighted-average number of shares used in
per share
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Anthera Announces Third Quarter 2010 Financial Report and Conference Call
2. Anthera Pharmaceuticals Announces Pricing of $31.5 Million PIPE Financing
3. Anthera Pharmaceuticals to Present at Deutsche Bank Securities 35th Annual Health Care Conference
4. Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
5. Antheras Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
6. Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
7. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
8. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
9. DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
10. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
11. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial